Targeting triple-negative breast cancer and high-grade ovarian carcinoma: Refining BRCAness beyond BRCA1/2 mutations?

Future Oncology

Volumn 11, Issue 4, 2015, Pages 557-559

  Jacot, William ^a,b   Theillet, Charles ^b   Guiu, Séverine ^a   Lamy, Pierre Jean ^a  

^a CENTRE VAL D AURELLE   (France)

^b INSERM   (France)

Author keywords

53BP1; BRCA1; breast cancer; methylation; ovarian cancer; targeted therapies

Indexed keywords

PLATINUM DERIVATIVE; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

CANCER GRADING; CANCER PATIENT; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC PREDISPOSITION; GENETIC STABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; NOTE; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; ANTAGONISTS AND INHIBITORS; DNA DAMAGE; DRUG EFFECTS; GENETICS; GENOMIC INSTABILITY; MOLECULARLY TARGETED THERAPY; MUTATION; OVARIAN NEOPLASMS; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM GRADING; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84923081294     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.268     Document Type: Note

References (26)

1. Liu X, Palma J, Kinders R et al. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal. Biochem. 381(2), 240-247 (2008).
2. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8(3), 193-204 (2008).
3. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J. Natl Cancer Inst. 96(22), 1659-1668 (2004).
4. Silver DP, Richardson AL, Eklund AC et al. Effcacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28 (7), 1145-1153 (2010).
5. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376(9737), 235-244 (2010).
6. Farmer H, Mccabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005).
7. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J. Clin. Oncol. 16 (5), 1969-1977 (1998).
8. Pal T, Permuth-Wey J, Betts JA et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12), 2807-2816 (2005).
9. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4 (10), 814-819 (2004).
10. Gelmon KA, Tischkowitz M, Mackay H et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a Phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12(9), 852-861 (2011).
11. Esteller M, Silva JM, Dominguez G et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92(7), 564-569 (2000).
12. Lips EH, Mulder L, Oonk A et al. Tr iple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br. J. Cancer 108 (10), 2172-2177 (2013).
13. Drew Y, Mulligan EA, Vong WT et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J. Natl Cancer Inst. 103 (4), 334-346 (2011).
14. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28(29), e563-e564; author reply e565-e566 (2010).
15. Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J. Biol. Chem. 289(13), 9247-9253 (2014).
16. Hughes-Davies L, Huntsman D, Ruas M et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5), 523-535 (2003).
17. Lips EH, Mulder L, Hannemann J et al. Indicators of homologous recombination defciency in breast cancer and association with response to neoadjuvant chemotherapy. Ann. Oncol. 22(4), 870-876 (2011).
18. Turner NC, Reis-Filho JS, Russell AM et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14), 2126-2132 (2007).
19. Konstantinopoulos PA, Spentzos D, Karlan BY et al. Gene expression profle of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28(22), 3555-3561 (2010).
20. Abkevich V, Timms KM, Hennessy BT et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br. J. Cancer 107(10), 1776-1782 (2012).
21. Popova T, Manie E, Rieunier G et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 72(21), 5454-5462 (2012).
22. Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 18 (8), 909-916 (2013).
23. Bouwman P, Aly A, Escandell JM et al. 53BP1 loss rescues BRCA1 defciency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17(6), 688-695 (2010).
24. Jaspers JE, Kersbergen A, Boon U et al. Loss of 53BP1 Causes parp inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3(1), 68-81 (2013).
25. Hill SJ, Clark A P, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol. Cell Biol. 34(20), 3828-3842 (2014).
26. Sakogawa K, Aoki Y, Misumi K et al. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition. Cancer Sci. 104 (12), 1593-1599 (2013).